Kidney Week 2022
Video and written summaries from ASN Kidney Week 2022 Annual Meeting, held from November 3 – 7, 2022.
Clinical Approach to IgA Nephropathy
With: Brian Mandell, MD, PhD, MACR, MACP and Jonathan Taliercio, DO, FASN
Brian Mandell, MD, PhD, MACR, MACP and Jonathan Taliercio, DO, FASN explore the clinical approach to IgA Nephropathy after attending a session at Kidney Week 2022.
Effects of Iptacopan on Proteinuria and Biomarkers in IgA Nephropathy
With: Brian Mandell, MD, PhD, MACR, MACP and Jonathan Taliercio, DO, FASN
Brian Mandell, MD, PhD, MACR, MACP and Jonathan Taliercio, DO, FASN review the abstract, Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy, presented at Kidney Week 2022.
Treatment Regimens for Kidney Disease
With: Brian Mandell, MD, PhD, MACR, MACP and Jonathan Taliercio, DO, FASN
Brian Mandell, MD, PhD, MACR, MACP and Jonathan Taliercio, DO, FASN discuss current and new treatment regimens for Kidney Disease, presented at Kidney Week 2022.
C3 Glomerulopathy Clinical Approach
With: Brian Mandell, MD, PhD, MACR, MACP and Ali Mehdi MD, MEd, FACP, FASN
Brian Mandell, MD, PhD, MACR, MACP and Ali Mehdi MD, MEd, FACP, FASN from Cleveland Clinic discuss the clinical approach and management of C3 Glomerulopathy after attending sessions at Kidney Week 2022.
Use of Iptacopan for C3 Glomerulopathy, Interim Analysis of Phase 2 Study
With: Brian Mandell, MD, PhD, MACR, MACP and Ali Mehdi MD, MEd, FACP, FASN
Brian Mandell, MD, PhD, MACR, MACP and Ali Mehdi MD, MEd, FACP, FASN from Cleveland Clinic review the abstract, 12M Interim Analysis of an Open-Label, Non-Randomized Extension of a Phase 2 Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Iptacopan in Subjects With C3G, presented at Kidney Week 2022.
Complement activation contributes to pathogenesis of IgA nephropathy, lupus nephritis; inhibitors under active investigation
Presenters: Nicholas R. Medjeral-Thomas, MBBS, PhD, Imperial College London; Brad H. Rovin, MD, The Ohio State University Wexner Medical Center, Columbus
A growing body of research demonstrates that complement plays a pathogenic role in IgA nephropathy and lupus nephritis (LN). Multiple agents investigating the targeting multiple arms of the complement activation pathway are under study in each disease, and the early data are promising.
C3G: Immunosuppressives have limited efficacy in reducing proteinuria; factor B inhibitor of alternative complement pathway performs well over long term
Presenters: Soumita Bagchi, MD, Nephrology Department, All India Institute of Medical Sciences, New Delhi, India; Carla M. Nester, MD, University of Iowa Molecular Otolaryngology and Renal Research Laboratories, Iowa City
Investigators in India found that patients with complement 3 glomerulopathy present young with proteinuria that is rarely responsive to immunotherapy, while a group in Iowa observed promising effects with iptacopan on proteinuria and estimated glomerular filtration rate.
Treatment of anemia in CKD is suboptimal; oral agents under investigation
Presenters: Bruce M. Robinson, MD, MS, FASN, Arbor Research Collaborative for Health, University of Michigan, Ann Arbor; Nupur Gupta, MD, Indiana University, Indianapolis
Anemia is managed inadequately in patients with early-stage chronic kidney disease and can be improved with better attention to monitoring.
Pipeline for Remission of Proteinuria in IgA Nephropathy is Encouraging
Presenters: Tingting Li, MD, MSc, FASN, Washington University, St. Louis, MO; Jonathan Barratt, MBChB, PhD, University of Leicester, United Kingdom; Richard A. Lafayette, MD, Stanford University Medical Center, Stanford, CA
Experts address the clinical implications of proteinuria in IgA nephropathy and discuss emerging treatment options.